{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:48:50Z","timestamp":1791676130690,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022LSW002"],"award-info":[{"award-number":["ZR2022LSW002"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH223"],"award-info":[{"award-number":["ZR2023MH223"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Binzhou Medical and Health Science and Technology Project","award":["BW20250028"],"award-info":[{"award-number":["BW20250028"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800169"],"award-info":[{"award-number":["81800169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Province Medical and Health Technology Development Plan Project","award":["202508011050"],"award-info":[{"award-number":["202508011050"]}]},{"name":"Yantai Natural Science Foundation","award":["ZR2025LZ041"],"award-info":[{"award-number":["ZR2025LZ041"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12904-6","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:40:24Z","timestamp":1791668424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hsa_circ_0029325 drives imatinib resistance via the CDCA4\/AKT axis in chronic myeloid leukemia"],"prefix":"10.1007","volume":"53","author":[{"given":"Xiaoxu","family":"Lan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenhui","family":"Ti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,10]]},"reference":[{"issue":"4","key":"12904_CR1","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","volume":"37","author":"TP Braun","year":"2020","unstructured":"Braun TP, Eide CA, Druker BJ (2020) Response and resistance to bcr-abl1-targeted therapies. Cancer Cell 37(4):530\u2013542. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.006","journal-title":"Cancer Cell"},{"issue":"11","key":"12904_CR2","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H (2024) Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol 99(11):2191\u20132212. https:\/\/doi.org\/10.1002\/ajh.27443","journal-title":"Am J Hematol"},{"issue":"12","key":"12904_CR3","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.26355\/eurrev_202306_32786","volume":"27","author":"UY Malkan","year":"2023","unstructured":"Malkan UY, Haznedaroglu IC (2023) Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system. Eur Rev Med Pharmacol Sci 27(12):5493\u20135506. https:\/\/doi.org\/10.26355\/eurrev_202306_32786","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"12904_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s11899-022-00679-z","volume":"17","author":"JJ Ng","year":"2022","unstructured":"Ng JJ, Ong ST (2022) Therapy resistance and disease progression in cml: mechanistic links and therapeutic strategies. Curr Hematol Malig Rep 17(6):181\u2013197. https:\/\/doi.org\/10.1007\/s11899-022-00679-z","journal-title":"Curr Hematol Malig Rep"},{"issue":"12","key":"12904_CR5","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","volume":"4","author":"C Vener","year":"2020","unstructured":"Vener C, Banzi R, Ambrogi F et al (2020) First-line imatinib vs second- and third-generation tkis for chronic-phase cml: a systematic review and meta-analysis. Blood Adv 4(12):2723\u20132735. https:\/\/doi.org\/10.1182\/bloodadvances.2019001329","journal-title":"Blood Adv"},{"issue":"1","key":"12904_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.7150\/ijbs.86305","volume":"20","author":"J Sun","year":"2024","unstructured":"Sun J, Hu R, Han M et al (2024) Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Biol Sci 20(1):175\u2013181. https:\/\/doi.org\/10.7150\/ijbs.86305","journal-title":"Int J Biol Sci"},{"key":"12904_CR7","doi-asserted-by":"publisher","first-page":"108697","DOI":"10.1016\/j.pharmthera.2024.108697","volume":"261","author":"J Zhang","year":"2024","unstructured":"Zhang J, Xu X, Deng H et al (2024) Overcoming cancer drug-resistance calls for novel strategies targeting abnormal alternative splicing. Pharmacol Ther 261:108697. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108697","journal-title":"Pharmacol Ther"},{"issue":"1","key":"12904_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13046-025-03482-9","volume":"44","author":"R Guan","year":"2025","unstructured":"Guan R, Li C, Jiao R et al (2025) MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K\/AKT\/mTOR signaling pathway. J Exp Clin Cancer Res 44(1):221. https:\/\/doi.org\/10.1186\/s13046-025-03482-9","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"12904_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s13046-019-1178-z","volume":"38","author":"Z Chen","year":"2019","unstructured":"Chen Z, Qi J, Wu Q et al (2019) Eukaryotic initiation factor 4a2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer. J Exp Clin Cancer Res 38(1):196. https:\/\/doi.org\/10.1186\/s13046-019-1178-z","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"12904_CR10","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1002\/1878-0261.13684","volume":"18","author":"I Kawahara","year":"2024","unstructured":"Kawahara I, Yoshino H, Fukumoto W et al (2024) Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Mol Oncol 18(9):2196\u20132211. https:\/\/doi.org\/10.1002\/1878-0261.13684","journal-title":"Mol Oncol"},{"issue":"1","key":"12904_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.7150\/thno.117590","volume":"16","author":"Y Wang","year":"2026","unstructured":"Wang Y, Chang Z, Sun Z et al (2026) Targeting the ARL4C\/RAP1\/PI3K-Akt-mTOR signaling loop promotes ARL4C ubiquitination and reverses oxaliplatin resistance in colorectal cancer. Theranostics 16(1):99\u2013122. https:\/\/doi.org\/10.7150\/thno.117590","journal-title":"Theranostics"},{"key":"12904_CR12","doi-asserted-by":"publisher","first-page":"1480572","DOI":"10.3389\/fimmu.2024.1480572","volume":"15","author":"Y Gong","year":"2024","unstructured":"Gong Y, Gong D, Liu S et al (2024) Deciphering the role of ncrnas in pancreatic cancer immune evasion and drug resistance: a new perspective for targeted therapy. Front Immunol 15:1480572. https:\/\/doi.org\/10.3389\/fimmu.2024.1480572","journal-title":"Front Immunol"},{"issue":"38","key":"12904_CR13","doi-asserted-by":"publisher","first-page":"eadp334","DOI":"10.1126\/sciadv.adp0334","volume":"10","author":"J Xu","year":"2024","unstructured":"Xu J, Zhao X, Liang X et al (2024) Development of mirna-based protacs targeting lin28 for breast cancer therapy. Sci Adv 10(38):eadp334. https:\/\/doi.org\/10.1126\/sciadv.adp0334","journal-title":"Sci Adv"},{"issue":"3","key":"12904_CR14","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1006\/bcmd.2001.0434","volume":"27","author":"JM Abdullah","year":"2001","unstructured":"Abdullah JM, Jing X, Spassov DS et al (2001) Cloning and characterization of hepp, a novel gene expressed preferentially in hematopoietic progenitors and mature blood cells. Blood Cells Mol Dis 27(3):667\u2013676. https:\/\/doi.org\/10.1006\/bcmd.2001.0434","journal-title":"Blood Cells Mol Dis"},{"key":"12904_CR15","doi-asserted-by":"publisher","first-page":"826337","DOI":"10.3389\/fimmu.2022.826337","volume":"13","author":"H Fang","year":"2022","unstructured":"Fang H, Sheng S, Chen B et al (2022) A pan-cancer analysis of the oncogenic role of cell division cycle-associated protein 4 (cdca4) in human tumors. Front Immunol 13:826337. https:\/\/doi.org\/10.3389\/fimmu.2022.826337","journal-title":"Front Immunol"},{"issue":"2","key":"12904_CR16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s00432-025-06109-w","volume":"151","author":"P Wan","year":"2025","unstructured":"Wan P, Ren Y, Deng H et al (2025) Cdca4 promotes bladder cancer progression by jak\/stat signaling pathway. J Cancer Res Clin Oncol 151(2):46. https:\/\/doi.org\/10.1007\/s00432-025-06109-w","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"12904_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12935-021-01754-w","volume":"21","author":"C Xu","year":"2021","unstructured":"Xu C, Cao H, Sui Y et al (2021) Cdca4 suppresses epithelial-mesenchymal transtion (emt) and metastasis in non-small cell lung cancer through modulating autophagy. Cancer Cell Int 21(1):48. https:\/\/doi.org\/10.1186\/s12935-021-01754-w","journal-title":"Cancer Cell Int"},{"key":"12904_CR18","doi-asserted-by":"publisher","first-page":"637755","DOI":"10.3389\/fgene.2021.637755","volume":"12","author":"S Hao","year":"2021","unstructured":"Hao S, Zhu J, Zhang X et al (2021) Comprehensive analysis of aerobic exercise-related genes identifies cdca4 that promotes the progression of osteosarcoma. Front Genet 12:637755. https:\/\/doi.org\/10.3389\/fgene.2021.637755","journal-title":"Front Genet"},{"issue":"5","key":"12904_CR19","doi-asserted-by":"publisher","first-page":"e12949","DOI":"10.1002\/kjm2.12949","volume":"41","author":"S Wu","year":"2025","unstructured":"Wu S, Hou X, Wang F et al (2025) IGF2BP2-induced circRNF20 facilitates breast cancer cell proliferation via the HuR\/CDCA4 axis. Kaohsiung J Med Sci 41(5):e12949. https:\/\/doi.org\/10.1002\/kjm2.12949","journal-title":"Kaohsiung J Med Sci"},{"issue":"1","key":"12904_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12935-021-01994-w","volume":"21","author":"P Ren","year":"2021","unstructured":"Ren P, Chang L, Hong X et al (2021) Long non-coding rna linc01116 is activated by egr1 and facilitates lung adenocarcinoma oncogenicity via targeting mir-744-5p\/cdca4 axis. Cancer Cell Int 21(1):292. https:\/\/doi.org\/10.1186\/s12935-021-01994-w","journal-title":"Cancer Cell Int"},{"issue":"2","key":"12904_CR21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11010-021-04286-z","volume":"477","author":"J Ju","year":"2022","unstructured":"Ju J, Song Y, Chen X et al (2022) Circrna is a potential target for cardiovascular diseases treatment. Mol Cell Biochem 477(2):417\u2013430. https:\/\/doi.org\/10.1007\/s11010-021-04286-z","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"12904_CR22","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-022-01345-w","volume":"15","author":"X Wang","year":"2022","unstructured":"Wang X, Chen T, Li C et al (2022) Circrna-creit inhibits stress granule assembly and overcomes doxorubicin resistance in tnbc by destabilizing pkr. J Hematol Oncol 15(1):122. https:\/\/doi.org\/10.1186\/s13045-022-01345-w","journal-title":"J Hematol Oncol"},{"issue":"1","key":"12904_CR23","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10717544.2022.2057617","volume":"29","author":"H Xie","year":"2022","unstructured":"Xie H, Yao J, Wang Y et al (2022) Exosome-transmitted circvmp1 facilitates the progression and cisplatin resistance of non-small cell lung cancer by targeting mir-524-5p-mettl3\/sox2 axis. Drug Deliv 29(1):1257\u20131271. https:\/\/doi.org\/10.1080\/10717544.2022.2057617","journal-title":"Drug Deliv"},{"key":"12904_CR24","doi-asserted-by":"publisher","first-page":"147917","DOI":"10.1016\/j.gene.2023.147917","volume":"893","author":"R Zhang","year":"2024","unstructured":"Zhang R, Hao J, Yu H et al (2024) Circ_sirt1 upregulates atg12 to facilitate imatinib resistance in cml through interacting with eif4a3. Gene 893:147917. https:\/\/doi.org\/10.1016\/j.gene.2023.147917","journal-title":"Gene"},{"issue":"7","key":"12904_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1089\/cbr.2020.3600","volume":"39","author":"H Che","year":"2024","unstructured":"Che H, Ding H, Jia X (2024) Circ_0080145 enhances imatinib resistance of chronic myeloid leukemia by regulating mir-326\/ppfia1 axis. Cancer Biother Radiopharm 39(7):478\u2013491. https:\/\/doi.org\/10.1089\/cbr.2020.3600","journal-title":"Cancer Biother Radiopharm"},{"key":"12904_CR26","doi-asserted-by":"publisher","first-page":"728916","DOI":"10.3389\/fphar.2021.728916","volume":"12","author":"A Zhong","year":"2021","unstructured":"Zhong A, Yin Y, Tang B et al (2021) Circrna microarray profiling reveals hsa_circ_0058493 as a novel biomarker for imatinib-resistant cml. Front Pharmacol 12:728916. https:\/\/doi.org\/10.3389\/fphar.2021.728916","journal-title":"Front Pharmacol"},{"issue":"9","key":"12904_CR27","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.3390\/biom15091245","volume":"15","author":"Y Hekmatshoar","year":"2025","unstructured":"Hekmatshoar Y, Ozkan T, Karabay AZ et al (2025) Targeting Integrin \u03b12 to Overcome Imatinib Resistance in Chronic Myeloid Leukemia Cells. Biomolecules 15(9):1245. https:\/\/doi.org\/10.3390\/biom15091245","journal-title":"Biomolecules"},{"issue":"1","key":"12904_CR28","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12964-022-01021-z","volume":"20","author":"F Zeng","year":"2022","unstructured":"Zeng F, Peng Y, Qin Y et al (2022) Wee1 promotes cell proliferation and imatinib resistance in chronic myeloid leukemia via regulating dna damage repair dependent on atm-gammah2ax-mdc1. Cell Commun Signal 20(1):199. https:\/\/doi.org\/10.1186\/s12964-022-01021-z","journal-title":"Cell Commun Signal"},{"issue":"1","key":"12904_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s40164-024-00589-1","volume":"13","author":"H Duan","year":"2024","unstructured":"Duan H, Lai Q, Jiang Y et al (2024) Chiglitazar diminishes the warburg effect through ppargamma\/mtor\/pkm2 and increases the sensitivity of imatinib in chronic myeloid leukemia. Exp Hematol Oncol 13(1):121. https:\/\/doi.org\/10.1186\/s40164-024-00589-1","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"12904_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s11658-023-00496-z","volume":"28","author":"X Zhang","year":"2023","unstructured":"Zhang X, Wang Y, Lu J et al (2023) A conserved zfx\/wnt3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem\/progenitor cells. Cell Mol Biol Lett 28(1):83. https:\/\/doi.org\/10.1186\/s11658-023-00496-z","journal-title":"Cell Mol Biol Lett"},{"issue":"1","key":"12904_CR31","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12032-014-0378-9","volume":"32","author":"B Zhou","year":"2015","unstructured":"Zhou B, Bu G, Zhou Y et al (2015) Knockdown of cdc2 expression inhibits proliferation, enhances apoptosis, and increases chemosensitivity to temozolomide in glioblastoma cells. Med Oncol 32(1):378. https:\/\/doi.org\/10.1007\/s12032-014-0378-9","journal-title":"Med Oncol"},{"issue":"1","key":"12904_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12943-024-01996-y","volume":"23","author":"J Cui","year":"2024","unstructured":"Cui J, Liu X, Shang Q et al (2024) Deubiquitination of cdc6 by otud6a promotes tumour progression and chemoresistance. Mol Cancer 23(1):86. https:\/\/doi.org\/10.1186\/s12943-024-01996-y","journal-title":"Mol Cancer"},{"key":"12904_CR33","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.2147\/CMAR.S333830","volume":"13","author":"J Zhang","year":"2021","unstructured":"Zhang J, Chen J, Ruan H et al (2021) Microribonucleic acid-15a-5p alters adriamycin resistance in breast cancer cells by targeting cell division cycle-associated protein 4. Cancer Manag Res 13:8425\u20138434. https:\/\/doi.org\/10.2147\/CMAR.S333830","journal-title":"Cancer Manag Res"},{"issue":"1","key":"12904_CR34","doi-asserted-by":"publisher","first-page":"e295346","DOI":"10.1371\/journal.pone.0295346","volume":"19","author":"R Li","year":"2024","unstructured":"Li R, Chen Y, Yang B et al (2024) Integrated bioinformatics analysis and experimental validation identified cdca families as prognostic biomarkers and sensitive indicators for rapamycin treatment of glioma. PLoS ONE 19(1):e295346. https:\/\/doi.org\/10.1371\/journal.pone.0295346","journal-title":"PLoS ONE"},{"issue":"6","key":"12904_CR35","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3390\/genes16060696","volume":"16","author":"L Chen","year":"2025","unstructured":"Chen L, Gao Y, Hu Z et al (2025) Identifying CDCA4 as a Radiotherapy Resistance-Associated Gene in Colorectal Cancer by an Integrated Bioinformatics Analysis Approach. Genes (Basel) 16(6):696. https:\/\/doi.org\/10.3390\/genes16060696","journal-title":"Genes (Basel)"},{"issue":"4","key":"12904_CR36","doi-asserted-by":"publisher","first-page":"100046","DOI":"10.1016\/j.clnves.2025.100046","volume":"1","author":"F Meng","year":"2025","unstructured":"Meng F, Li H, Wang Y et al (2025) The mechanism of AKT activation in cancer. Cell Invest 1(4):100046. https:\/\/doi.org\/10.1016\/j.clnves.2025.100046","journal-title":"Cell Invest"},{"key":"12904_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer IA, Arteaga CL (2016) The pi3k\/akt pathway as a target for cancer treatment. Annu Rev Med 67:11\u201328. https:\/\/doi.org\/10.1146\/annurev-med-062913-051343","journal-title":"Annu Rev Med"},{"issue":"6","key":"12904_CR38","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1007\/s11030-025-11132-7","volume":"29","author":"BH Kumar","year":"2025","unstructured":"Kumar BH, Kabekkodu SP, Pai KSR (2025) Structural insights of AKT and its activation mechanism for drug development. Mol Divers 29(6):5443\u20135463. https:\/\/doi.org\/10.1007\/s11030-025-11132-7","journal-title":"Mol Divers"},{"issue":"4","key":"12904_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.7150\/ijbs.83774","volume":"20","author":"W Du","year":"2024","unstructured":"Du W, Tu S, Zhang W et al (2024) Upp1 enhances bladder cancer progression and gemcitabine resistance through akt. Int J Biol Sci 20(4):1389\u20131409. https:\/\/doi.org\/10.7150\/ijbs.83774","journal-title":"Int J Biol Sci"},{"key":"12904_CR40","doi-asserted-by":"publisher","first-page":"109659","DOI":"10.1016\/j.cbi.2021.109659","volume":"349","author":"L Ma","year":"2021","unstructured":"Ma L, Zhang R, Li D et al (2021) Fluoride regulates chondrocyte proliferation and autophagy via pi3k\/akt\/mtor signaling pathway. Chem Biol Interact 349:109659. https:\/\/doi.org\/10.1016\/j.cbi.2021.109659","journal-title":"Chem Biol Interact"},{"issue":"12","key":"12904_CR41","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.1080\/15548627.2021.1905466","volume":"17","author":"W Liu","year":"2021","unstructured":"Liu W, Xu L, Wang X et al (2021) Prdx1 activates autophagy via the pten-akt signaling pathway to protect against cisplatin-induced spiral ganglion neuron damage. Autophagy 17(12):4159\u20134181. https:\/\/doi.org\/10.1080\/15548627.2021.1905466","journal-title":"Autophagy"},{"key":"12904_CR42","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","volume":"103","author":"J Yang","year":"2018","unstructured":"Yang J, Pi C, Wang G (2018) Inhibition of pi3k\/akt\/mtor pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother 103:699\u2013707. https:\/\/doi.org\/10.1016\/j.biopha.2018.04.072","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"12904_CR43","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.62347\/RWLJ3990","volume":"14","author":"W He","year":"2024","unstructured":"He W, Liu S, Wei W et al (2024) mTOR inhibition by AZD2014 alleviates BCR::ABL1 independent imatinib resistance through enhancing autophagy in CML resistant cells. Am J Cancer Res 14(6):2770\u20132789. https:\/\/doi.org\/10.62347\/RWLJ3990","journal-title":"Am J Cancer Res"},{"issue":"4","key":"12904_CR44","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/cbdd.14283","volume":"102","author":"J Han","year":"2023","unstructured":"Han J, Wang Y (2023) Hsa-mir-503-5p regulates ctdspl to accelerate cisplatin resistance and angiogenesis of lung adenocarcinoma cells. Chem Biol Drug Des 102(4):749\u2013762. https:\/\/doi.org\/10.1111\/cbdd.14283","journal-title":"Chem Biol Drug Des"},{"issue":"20","key":"12904_CR45","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1080\/15384101.2023.2281768","volume":"22","author":"Z Chen","year":"2023","unstructured":"Chen Z, Xu Z, Wang Q et al (2023) Exosome-delivered circrna circsyt15 contributes to cisplatin resistance in cervical cancer cells through the mir-503-5p\/rsf1 axis. Cell Cycle 22(20):2211\u20132228. https:\/\/doi.org\/10.1080\/15384101.2023.2281768","journal-title":"Cell Cycle"},{"issue":"11","key":"12904_CR46","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/s41594-018-0136-3","volume":"25","author":"K Zhang","year":"2018","unstructured":"Zhang K, Zhang X, Cai Z et al (2018) A novel class of microrna-recognition elements that function only within open reading frames. Nat Struct Mol Biol 25(11):1019\u20131027. https:\/\/doi.org\/10.1038\/s41594-018-0136-3","journal-title":"Nat Struct Mol Biol"},{"issue":"18","key":"12904_CR47","doi-asserted-by":"publisher","first-page":"9938","DOI":"10.1093\/nar\/gkad645","volume":"51","author":"S Sapkota","year":"2023","unstructured":"Sapkota S, Pillman KA, Dredge BK et al (2023) On the rules of engagement for micrornas targeting protein coding regions. Nucleic Acids Res 51(18):9938\u20139951. https:\/\/doi.org\/10.1093\/nar\/gkad645","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"12904_CR48","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12943-020-01286-3","volume":"19","author":"W Zhou","year":"2020","unstructured":"Zhou W, Cai Z, Liu J et al (2020) Circular rna: metabolism, functions and interactions with proteins. Mol Cancer 19(1):172. https:\/\/doi.org\/10.1186\/s12943-020-01286-3","journal-title":"Mol Cancer"},{"issue":"1","key":"12904_CR49","doi-asserted-by":"publisher","first-page":"gkae1167","DOI":"10.1093\/nar\/gkae1167","volume":"53","author":"G Margvelani","year":"2025","unstructured":"Margvelani G, Maquera KAA, Welden JR et al (2025) Translation of circular RNAs. Nucleic Acids Res 53(1):gkae1167. https:\/\/doi.org\/10.1093\/nar\/gkae1167","journal-title":"Nucleic Acids Res"},{"issue":"1\u20132","key":"12904_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/carcin\/bgad079","volume":"45","author":"B Qu","year":"2024","unstructured":"Qu B, Sun L, Xiao P et al (2024) Circcdk17 promotes the proliferation and metastasis of ovarian cancer cells by sponging mir-22-3p to regulate cd147 expression. Carcinogenesis 45(1\u20132):83\u201394. https:\/\/doi.org\/10.1093\/carcin\/bgad079","journal-title":"Carcinogenesis"},{"issue":"34","key":"12904_CR51","doi-asserted-by":"publisher","first-page":"e2304895","DOI":"10.1002\/advs.202304895","volume":"10","author":"Z Wu","year":"2023","unstructured":"Wu Z, Zuo X, Zhang W et al (2023) M6a-modified circtet2 interacting with hnrnpc regulates fatty acid oxidation to promote the proliferation of chronic lymphocytic leukemia. Adv Sci (Weinh) 10(34):e2304895. https:\/\/doi.org\/10.1002\/advs.202304895","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"12904_CR52","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-024-01940-0","volume":"23","author":"B Huang","year":"2024","unstructured":"Huang B, Ren J, Ma Q et al (2024) A novel peptide pdhk1-241aa encoded by circpdhk1 promotes ccrcc progression via interacting with ppp1ca to inhibit akt dephosphorylation and activate the akt-mtor signaling pathway. Mol Cancer 23(1):34. https:\/\/doi.org\/10.1186\/s12943-024-01940-0","journal-title":"Mol Cancer"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12904-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12904-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:06:45Z","timestamp":1791673605000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12904-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,10]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12904"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12904-6","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,10]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We the authors directly participated in the planning, execution, and analysis of our submission and have read and approved the final version. All authors are consent for the publication. As stated, written informed consent was obtained from all participants for both participation in the study and publication of the results.","order":1,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"<b>Ethics declaration<\/b>"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"<b>Ethics declaration<\/b>"}},{"value":"All clinical samples were recruited from the Affiliated Hospital of Binzhou Medical University (Shandong, China). The Medical Ethics Committee of Binzhou Medical University approved this study (Approval No. 2021\u2009\u2212\u2009126), with all subjects providing written consent. The research was carried out in strict accordance with the guidelines stipulated by the aforementioned ethics committee as stated in the ethics statement. All mice experiments were performed following institutional guidelines and approved by the Ethics Committee for Animal Experiments of Binzhou Medical University (Shandong, China) (Approval No. 2021\u2009\u2212\u20090128).","order":3,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"<b>Ethics declaration<\/b>"}}],"article-number":"1702"}}